Andrew Oxtoby, Chief Commercial Officer at Aimmune Therapeutics, Inc. (AIMT), bought 3,000 shares at $14.76 ($44K) on 2020-03-13, disclosed to the SEC on 2020-03-17.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.